02. Sequence Listing

SEQUENCE LISTING

<110> GUANGZHOU CELLPROTEK PHARMACEUTICAL CO., LTD

<120> HEXOKINASE 2-SPECIFIC INHIBITORS FOR USE IN ACUTE CENTRAL NERVOUS SYSTEM INJURY

<130> 191407SG

<160> 23

<170> PatentIn version 3.5

<210> 1
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> HK1 Forward Primers

<400> 1
gtaggggtac gcttaggtgg 20

<210> 2
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> HK1 Reverse Primers

<400> 2
acccaggagt ccataaagcc 20

<210> 3
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> HK2 Forward Primers

<400> 3
gagaaagctc agcatcgtgg 20

<210> 4
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> HK2 Reverse Primers

<400> 4
tccatttgta ctccgtggct 20

<210> 5
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> HK3 Forward Primers

<400> 5
gctccgttga gagcagattt 20

<210> 6
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> HK3 Reverse Primers

<400> 6
ttgctgcaag cattccagtt 20

<210> 7
<211> 21
<212> DNA
<213> Artificial Sequence

<220>
<223> PFKM Forward Primers

<400> 7
gtttggaagc ctctcctcct c 21

<210> 8
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> PFKM Reverse Primers

<400> 8
gacggcagca ttcatacctt 20

<210> 9
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> PFKL Forward Primers

<400> 9
cgcaaggtat gaatgctgct 20

<210> 10
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> PFKL Reverse Primers

<400> 10
cgatggtcaa gtgtgcgtag 20

<210> 11
<211> 20
<212> DNA

<213> Artificial Sequence

<220>
<223> PGK1 Forward Primers

<400> 11
cgagcctcac tgtccaaact 20

<210> 12
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> PGK1 Reverse Primers

<400> 12
gtctgcaact ttagcgcctc 20

<210> 13
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> PKM1 Forward Primers

<400> 13
cgtccgcagg tttgatgaga 20

<210> 14
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> PKM1 Reverse Primers

<400> 14
ttcaaacagc agacggtgga 20

<210> 15
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> PKM2 Forward Primers

<400> 15
ggctcctatc attgccgtga 20

<210> 16
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> PKM2 Reverse Primers

<400> 16
aaggtacagg cactacacgc 20

<210> 17
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Actb Forward Primers

<400> 17
tgagctgcgt tttacaccct 20

<210> 18
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Actb Reverse Primers

<400> 18
tttgggggat gtttgctcca 20

<210> 19
<211> 21
<212> DNA
<213> Artificial Sequence

<220>
<223> Il1b promoter primer (forward)

<400> 19
aggtcaaagg tttggaagca g 21

<210> 20
<211> 25
<212> DNA
<213> Artificial Sequence

<220>
<223> Il1b promoter primer (reverse)

<400> 20
atggaagtct gtctgctcag tattg 25

<210> 21
<211> 21
<212> DNA
<213> Artificial Sequence

<220>
<223> the sequences targeting HK2

<400> 21
gcgcaacatt ctcatcgatt t 21

<210> 22
<211> 21
<212> DNA
<213> Artificial Sequence

<220>
<223> the sequences targeting HK2

<400> 22
aaatcgatga gaatgttgcg c 21

<210> 23
<211> 19
<212> DNA
<213> Artificial Sequence

<220>
<223> control shRNA sequence

<400> 23
ttctccgaac gtgtcacgt 19